Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7608461 | 0.90 | LRRK2 (0.59) | LRRK2CYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL7606181 | 0.90 | LRRK2 (0.55) | LRRK2CYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL7606217 | 0.88 | LRRK2 (0.50) | LRRK2CYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL7606069 | 0.86 | HDAC6 (0.53) | LRRK2CYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL7607146 | 0.83 | LRRK2 (0.50) | LRRK2CYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL7612625 | 0.83 | SGMS2 (0.50) | LRRK2HDAC1HDAC6SGMS2RHEB | |
| SCHEMBL7611336 | 0.81 | LRRK2 (0.55) | LRRK2HDAC1HDAC6SGMS2POLB | |
| SCHEMBL7613476 | 0.80 | HDAC1 (0.49) | LRRK2HDAC1HDAC6SGMS2POLB | |
| SCHEMBL7607184 | 0.79 | LRRK2 (0.49) | LRRK2CYP11B1CYP11B2HDAC1HDAC6 | |
| SCHEMBL7609787 | 0.79 | HDAC1 (0.53) | HDAC1HDAC6POLBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436965-B1 | INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-08-20 | — | — | US | claimed |
| US-20020068756-A1 | PDE IV inhibiting amides, compositions and methods of treatment | MERCK FROSST CANADA LTD. (CA) | 2002-06-06 | — | — | US | claimed |
| US-6436965-B1 | INHIBITION OF PHOSPHODIESTERASE; 3-CARBOCYCLIC(ALKYL)OXY-2-ARYL(ALKYL)AMINOCARBONYL-1-ARYL(ALKYL)INDOLE OR AZAINDOLE DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-08-20 | — | — | US | disclosed |
| US-20020068756-A1 | PDE IV inhibiting amides, compositions and methods of treatment | MERCK FROSST CANADA LTD. (CA) | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068756-A1 | PDE IV inhibiting amides, compositions and methods of treatment | PDE3A, PDE3B, PDE4A | LRRK2 4594/4885CYP11B1 174/4885CYP11B2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.